-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59

Benzinga·11/06/2026 16:24:55
Listen to the news
Guggenheim analyst Michael Schmidt maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and lowers the price target from $60 to $59.